Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24315790 | 0.97 | PTGDR2 (0.43) | PTGDR2ALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL26620346 | 0.86 | PTGDR2 (0.46) | PTGDR2ALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL26620045 | 0.83 | PTGDR2 (0.46) | PTGDR2ALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL27010386 | 0.82 | ALDH1A1 (0.57) | PTGDR2ALDH1A1SMN1; SMN2GAATSHR | |
| SCHEMBL27010239 | 0.81 | PTGDR2 (0.42) | PTGDR2ALDH1A1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL27010235 | 0.80 | PTGDR2 (0.45) | PTGDR2ALDH1A1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL27010256 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAATSHRPOLB | |
| SCHEMBL24315682 | 0.79 | L3MBTL1 (0.48) | ALDH1A1SMN1; SMN2L3MBTL1POLBATM | |
| SCHEMBL27010306 | 0.79 | PTGDR2 (0.46) | PTGDR2ALDH1A1SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL24315678 | 0.78 | PTGDR2 (0.43) | PTGDR2ALDH1A1SMN1; SMN2L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | PTGDR2 2093/4885ALDH1A1 2267/4885SMN1; SMN2 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.